跳至主要内容
临床试验/ACTRN12624000032550
ACTRN12624000032550尚未招募3 期

The effect of ertugliflozin on liver function in patients with nonalcoholic fatty liver disease (NAFLD) associated with type 2 diabetes mellitus.

Abdul Wali Khan University0 个研究点目标入组 180 人开始时间: 2024年1月15日最近更新:
适应症

试验速览

阶段
3 期
状态
尚未招募
发起方
入组人数
180

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Blinded (masking used)

入排标准

年龄范围
20 Years 至 70 Years(—)
性别
All

入选标准

  • Participants for this RCT must be Adult patients (above age of 20 years), diagnosed with non alcoholic fatty liver diseases along with type 2 diabetes mellitus.

排除标准

  • Participants not having non alcoholic fatty liver diseases along with type 2 diabetes mellitus., not willing to participate and the patient having elevated liver enzyme with any other risk factor such as hepatitis.

研究者

发起方
Abdul Wali Khan University

相似试验